Page 97 - Genentech News Today

On May 18, 2023, the Supreme Court in Amgen Inc. v. Sanofi unanimously affirmed the Federal Circuit’s holding that U.S. Patent Nos. 8,829,165 and 8,859,741 did not enable certain...

Crispr Therapeutics AG (CRSP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sali...

Senolytics and cellular rejuvenation could hold the key | Technology Quarterly

At the National Comprehensive Cancer Network Oncology Policy Summit, prominent figures in the health care industry from diverse organizations emphasized a commitment to advancing health equity and addressing pressing social and health disparities.

With the 2023 Arizona State of Reform Health Policy Conference coming up next month, we wanted to share the list of organizations that will be attending our event.

As healthcare gets ever more personalized, Genentech is expanding innovation from the lab into marketing, in service of “science for good.” The biotech pioneer’s chief marketing officer tells how.

The question of which expertise to trust has always been a tricky, sometimes even touchy subject. Nowhere is this better evidenced than the COVID-19 crisis. Every nation in the world – from Sweden to Saudi Arabia has had its own scientific community put under the microscope. Misinformation continues to circula...

Compared to white women, Black women die from breast cancer at a rate that is 41% higher. Black women under […] The post In anticipation of Breast Cancer Awareness Month, White House spotlights org that helps boost Black participation in clinical trial appeared first on TheGrio.

The U.S. Court of Appeals for the Federal Circuit (CAFC) today affirmed a district court’s grant of summary judgment that Baxalta, Inc. and Baxalta GmbH’s Hemophilia patent claims are invalid for a lack of enablement. The court said the facts of the case are “materially indistinguishable from those in Amgen.”

BioPharma